EMA revokes eight class waivers for PIPs to 'encourage' development of drugs for children

The European Medicines Agency has revoked eight class waivers for pediatric investigation plans (PIPs) in a bid to encourage companies to develop more new medicines for use in children. The agency has also confirmed nine class waivers on its current list of class waivers, which means there continues to be no requirement for PIPs for medicines for treating these diseases, and it has updated 15 class waivers on the list1-5.

The European Medicines Agency has revoked eight class waivers for pediatric investigation plans (PIPs) in a bid to encourage companies to develop more new medicines for use in children. The agency has also confirmed nine class waivers on its current list of class waivers, which means there continues to be no requirement for PIPs for medicines for treating these diseases, and it has updated 15 class waivers on the list1-5.

The changes to the class waiver list are the most extensive revisions that the EMA has made to the list,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet